Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

ClinicalTrials.gov ID: NCT03248128

Public ClinicalTrials.gov record NCT03248128. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids

Study identification

NCT ID
NCT03248128
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
906 participants

Conditions and interventions

Conditions

Interventions

  • FF/VI via ELLIPTA DPI Drug
  • FF via ELLIPTA DPI Drug

Drug

Eligibility (public fields only)

Age range
5 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 19, 2017
Primary completion
Mar 20, 2022
Completion
Mar 20, 2022
Last update posted
Jun 21, 2025

2017 – 2022

United States locations

U.S. sites
49
U.S. states
21
U.S. cities
41
Facility City State ZIP Site status
GSK Investigational Site Hoover Alabama 35244
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Huntington Beach California 92648
GSK Investigational Site Riverside California 92506
GSK Investigational Site Colorado Springs Colorado 80907
GSK Investigational Site Denver Colorado 80206
GSK Investigational Site Denver Colorado 80230
GSK Investigational Site Aventura Florida 33180
GSK Investigational Site Miami Florida 33134
GSK Investigational Site Miami Florida 33135
GSK Investigational Site Miami Florida 33142
GSK Investigational Site Miami Florida 33173
GSK Investigational Site Miami Florida 33186
GSK Investigational Site Miami Lakes Florida 33014
GSK Investigational Site Ocala Florida 34470
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Orlando Florida 32827
GSK Investigational Site Gainesville Georgia 30501
GSK Investigational Site Savannah Georgia 31406
GSK Investigational Site Evanston Illinois 60201
GSK Investigational Site Oak Park Illinois 60301
GSK Investigational Site Evansville Indiana 47715
GSK Investigational Site Owensboro Kentucky 42301
GSK Investigational Site Baltimore Maryland 21236
GSK Investigational Site White Marsh Maryland 21162
GSK Investigational Site Ypsilanti Michigan 48197
GSK Investigational Site Piscataway New Jersey 08854
GSK Investigational Site Verona New Jersey 07044
GSK Investigational Site Great Neck New York 11021
GSK Investigational Site New Hartford New York 13413
GSK Investigational Site Asheville North Carolina 28801
GSK Investigational Site Charlotte North Carolina 28277
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Grove City Ohio 43123
GSK Investigational Site Oklahoma City Oklahoma 73120
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Wexford Pennsylvania 15090
GSK Investigational Site Greenville South Carolina 29607
GSK Investigational Site Orangeburg South Carolina 29118-2040
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site Summerville South Carolina 29485
GSK Investigational Site Dallas Texas 75231-4307
GSK Investigational Site Houston Texas 77055
GSK Investigational Site Lewisville Texas 75067
GSK Investigational Site San Antonio Texas 78207
GSK Investigational Site San Antonio Texas 78215
GSK Investigational Site San Antonio Texas 78249
GSK Investigational Site Waco Texas 76712
GSK Investigational Site Murray Utah 84107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 134 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03248128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2025 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03248128 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →